Management of microscopic colitis: challenges and solutions

Area of Science:

• Gastroenterology
• Internal Medicine
• Pathology

Background:

• Microscopic colitis (MC) is a chronic inflammatory bowel disease causing nonbloody diarrhea with normal-appearing colonic mucosa.
• It encompasses collagenous colitis and lymphocytic colitis subtypes, sharing similar management goals.
• Treatment aims to reduce bowel movement frequency and improve stool consistency.

Purpose of the Study:

• To outline current management strategies for microscopic colitis.
• To identify first-line treatments and adjunctive therapies.
• To highlight the need for systematic approaches in relapsing and refractory cases.

Main Methods:

• Review of current treatment guidelines and literature for microscopic colitis.
• Identification of risk factors and associated medications to avoid.
• Summary of therapeutic options including glucocorticoids, budesonide, and other agents for refractory disease.

Main Results:

• First-line management includes risk factor modification (smoking cessation, avoiding NSAIDs, PPIs, ranitidine, sertraline) and symptomatic relief with loperamide.
• Budesonide is a preferred first-line treatment due to efficacy and safety, despite high relapse rates.
• Systemic glucocorticoids are reserved for cases where budesonide is not tolerated.

Conclusions:

• Current MC management focuses on budesonide as a first-line therapy.
• High relapse rates underscore the need for further research into managing refractory and relapsing MC.
• A systematic stepwise treatment algorithm is required for complex cases.